First head-to-head trial of obesity drugs reveals best jab for weight loss

The jab is more expensive than existing drugs but believed to be more effective -

The winner of the first major head-to-head study of weight loss jabs has been revealed.

The trial included 751 people from across the U.S. who were overweight or had obesity and at least one other weight-related health problem, but not diabetes. Participants received weekly injections of the highest tolerated doses of Zepbound, either 10 milligrams or 15 milligrams, or Wegovy, 1.7 milligrams or 2.4 milligrams.